½ÃÀ庸°í¼­
»óǰÄÚµå
1601596

¼¼°èÀÇ ½ÃƼÄݸ° ½ÃÀå : Á¦Ç°, ¿ëµµ, ¿¬·É´ë, À¯Åëä³Î, Áö¿ªº° ¿¹Ãø(-2032³â)

Global Citicoline Market Research Report Information by Product by Application, by Age Group by Distribution Channel, by Region Forecast till 2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Market Research Future | ÆäÀÌÁö Á¤º¸: ¿µ¹® 179 Pages | ¹è¼Û¾È³» : Áï½Ã¹è¼Û

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

½ÃƼÄݸ° ½ÃÀå ±Ô¸ð´Â 2023³â 4¾ï 3,000¸¸ ´Þ·¯, 2024³â 4¾ï 8,000¸¸ ´Þ·¯¿¡¼­ ¿¹Ãø ±â°£ µ¿¾È CAGR 8.99%·Î 2032³â¿¡´Â 10¾ï 4,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

½ÃÀå È®´ëÀÇ ¹è°æ¿¡´Â ÇÇÆ®´Ï½º ¹× ½ºÆ÷Ã÷ ºÐ¾ß ¼ö¿ä Áõ°¡, ÀÎÁö °Ç°­¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, Àü ¼¼°èÀÎÀÇ ¾ó±¼ ¹Ì¿ë¿¡ ´ëÇÑ ¿­¸Á Áõ°¡ µîÀÌ ÀÖ½À´Ï´Ù.

°í·ÉÈ­, ÀÎÁö±â´É °­È­¿¡ ´ëÇÑ ¿ä±¸, ½Å°æÁúȯ Áõ°¡°¡ ½ÃÀå È®´ëÀÇ ÁÖ¿ä ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. Àü »ý¾Ö¿¡ °ÉÃÄ ³ú °Ç°­°ú ÀÎÁö±â´ÉÀ» À¯ÁöÇÏ´Â °ÍÀÇ Á߿伺¿¡ ´ëÇÑ ´ëÁßÀÇ ÀνÄÀº ÃÖ±Ù ¸î ³âµ¿¾È Å©°Ô º¯È­Çϰí ÀÖ½À´Ï´Ù. Á¤º¸ Á¢±Ù¼º Áõ°¡, ³ëÀÎ Àα¸ Áõ°¡, ÀÎÁö ±â´É ÀúÇÏ ¹× ¾ËÃ÷ÇÏÀ̸Ӻ´°ú °°Àº ½Å°æ Áúȯ¿¡ ´ëÇÑ °ü½É Áõ°¡ µî ´Ù¾çÇÑ ¿äÀÎÀÌ ÀÌ·¯ÇÑ º¯È­¸¦ °¡Á®¿Ô½À´Ï´Ù.

Áö¿ªº° Àü¸Á

ºÏ¹Ì°¡ 2022³â °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ÀÌ´Â ºÏ¹ÌÀÇ ³ëÀÎ Àα¸ Áõ°¡, ¾ó±¼ ±³Á¤ ¹× °³¼± ¼ö¼úÀÇ º¸ÆíÈ­, 1ÀÎ´ç °¡Ã³ºÐ ¼ÒµæÀÌ »ó´çÈ÷ ³ô±â ¶§¹®À¸·Î ºÐ¼®µË´Ï´Ù.

¶ÇÇÑ, À¯·´Àº ÀǾàǰ ¹× ÀÇ·á ÀÎÇÁ¶ó°¡ Àß ±¸ÃàµÇ¾î ÀÖ°í, Áö¿ª Àüü°¡ °í·ÉÈ­µÇ¾î ÀÖ¾î ½ÃÀå Á¡À¯À² 2À§¸¦ Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ½ºÆäÀÎÀº À¯·´¿¡¼­ °¡Àå ºü¸¥ ¼Óµµ·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, µ¶ÀÏÀÌ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù.

¾Æ½Ã¾ÆÅÂÆò¾çÀº 2024³âºÎÅÍ 2032³â±îÁö »ó´çÇÑ ¼Óµµ·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ´Â ¾Æ½Ã¾ÆÅÂÆò¾çÀÌ ÀÎÁö °Ç°­¿¡ ´ëÇÑ Áö½ÄÀÌ Áõ°¡ÇÏ°í ½ÃÆ¼Äݸ° º¸ÃæÁ¦ÀÇ ÀÌÁ¡À» ÀÌÇØÇÏ°Ô µÇ¸é¼­ ³ªÅ¸³­ °á°úÀÔ´Ï´Ù. ÀÌ Áö¿ª¿¡¼­´Â Àεµ°¡ °¡Àå ºü¸¥ ¼Óµµ·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, Áß±¹ÀÌ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°è ½ÃƼÄݸ°(Citicoline) ½ÃÀåÀ» Á¶»çÇßÀ¸¸ç, ½ÃÀå Á¤ÀÇ¿Í °³¿ä, ½ÃÀå ¼ºÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â °¢Á¾ ¿µÇâ¿äÀÎ ºÐ¼®, ½ÃÀå ±Ô¸ð ÃßÀÌ ¹× ¿¹Ãø, °¢ ºÎ¹®º°/Áö¿ªº°/ÁÖ¿ä ±¹°¡º° ºÐ¼®, °æÀï ȯ°æ, ÁÖ¿ä ±â¾÷ ÇÁ·ÎÆÄÀÏ µîÀÇ Á¤º¸¸¦ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå °³¿ä

Á¦3Àå Á¶»ç ¹æ¹ý

Á¦4Àå ½ÃÀå ¿ªÇÐ

  • ¼ºÀå ÃËÁø¿äÀÎ
  • ¼ºÀå ¾ïÁ¦¿äÀÎ
  • ±âȸ
  • COVID-19ÀÇ ¼¼°è °æÁ¦¿¡ ´ëÇÑ ¿µÇâ
  • COVID-19°¡ ¼¼°èÀÇ ½ÃƼÄݸ° ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâ
  • °ø±Þ¸Á¿¡ ´ëÇÑ ¿µÇâ
  • ±ÔÁ¦ »óȲ

Á¦5Àå ½ÃÀå ¿äÀÎ ºÐ¼®

  • °ø±Þ/¹ë·ùüÀÎ ºÐ¼®
  • PorterÀÇ Five Forces ºÐ¼®

Á¦6Àå ¼¼°èÀÇ ½ÃƼÄݸ° ½ÃÀå : Á¦Ç°º°

  • °³¿ä
  • ½ÃÀå ±Ô¸ð ÃßÀÌ¿Í ¿¹Ãø
    • ĸ½¶
    • Á¤Á¦
    • ºÐ¸»
    • Á¡¾ÈÁ¦
    • ÁÖ»çÁ¦

Á¦7Àå ¼¼°èÀÇ ½ÃƼÄݸ° ½ÃÀå : ¿ëµµº°

  • °³¿ä
  • ½ÃÀå ±Ô¸ð ÃßÀÌ¿Í ¿¹Ãø
    • ½ºÆ÷Ã÷ ¿µ¾ç
    • ÆÛ½º³Î À£´Ï½º
    • Ä¡·á(³ì³»Àå, ³úÁ¹Áß, ¾ËÃ÷ÇÏÀ̸Ӻ´)

Á¦8Àå ¼¼°èÀÇ ½ÃƼÄݸ° ½ÃÀå : ¿¬·ÉÃþº°

  • °³¿ä
  • ½ÃÀå ±Ô¸ð ÃßÀÌ¿Í ¿¹Ãø
    • ¼Ò¾Æ
    • ¼ºÀÎ
    • °í·ÉÀÚ

Á¦9Àå ¼¼°èÀÇ ½ÃƼÄݸ° ½ÃÀå : À¯Åë ä³Îº°

  • °³¿ä
  • ½ÃÀå ±Ô¸ð ÃßÀÌ¿Í ¿¹Ãø
    • ¿Â¶óÀΠä³Î
    • ¿ÀÇÁ¶óÀΠä³Î

Á¦10Àå ¼¼°èÀÇ ½ÃƼÄݸ° ½ÃÀå : Áö¿ªº°

  • °³¿ä
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ±âŸ
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • È£ÁÖ
    • Çѱ¹
    • ±âŸ
  • ±âŸ Áö¿ª
    • Áßµ¿
    • ¾ÆÇÁ¸®Ä«
    • ¶óƾ¾Æ¸Þ¸®Ä«
    • Á߾ӾƸ޸®Ä«

Á¦11Àå °æÀï ±¸µµ

  • °æÀï °³¿ä
  • °æÀï º¥Ä¡¸¶Å·
  • ¼¼°èÀÇ ½ÃƼÄݸ° ½ÃÀå ÁÖ¿ä ±â¾÷

Á¦12Àå ±â¾÷ °³¿ä

  • KYOWA HAKKO BIO CO., LTD.
  • VITABIOTICS LTD
  • GRUPO FERRER INTERNACIONAL, S.A.
  • LIFE EXTENSION
  • UNION KOREA PHARM CO LTD
  • INVISION MEDI SCIENCES
  • RPG LIFE SCIENCES LTD
  • CHEMO BIOLOGICAL
  • CENTURY PHARMA
  • HARBIN PHARMACEUTICAL GROUP

Á¦13Àå ºÎ·Ï

LSH 24.12.17

Global Citicoline Market Research Report Information by Product (Capsules, Tablets, Powder, Eye Drops, and Injection) by Application (Sports Nutrition, Personal Wellness, Treatment [Glaucoma, Stroke, Alzheimer disease, Channel (pression, and Others]), by Age Group (Pediatric, Adult, and Geriatric) by Distribution Channel (Online Channel, Offline Channel), by Region (North America, Europe, Asia-Pacific, and Rest of the World) Forecast till 2032

Overview of the Market

The size of the Citicoline market was estimated at USD 0.43 billion in 2023 and is expected to increase at a compound annual growth rate (CAGR) of 8.99% from 2024 to 2032, from USD 0.48 billion in 2024 to USD 1.04 billion by 2032. The market is expanding due to the growing demand from the fitness and sports sectors, the growing awareness of cognitive health, and the growing desire for facial aesthetics worldwide.

According to the report, the aging population, the need for cognitive enhancement, and the rise in neurological illnesses are the primary drivers of the market's expansion. The public's understanding of the significance of preserving brain health and cognitive function throughout life has significantly changed in recent years. Numerous variables, such as increased information availability, an older population, and growing worries about cognitive decline and neurological disorders like Alzheimer's, are to blame for this change.

Market Segments Insights

Type-wise, the Citicoline market is divided into capsules, tablets, powder, eye drops, and injections.

Sports nutrition, personal wellbeing, and treatment are among the applications that form the basis of the market segmentation. Treatment is further divided into categories such as bipolar depression, Alzheimer's illness, stroke, and glaucoma.

The market for Citicoline is segmented by age group, including geriatric, adult, and Pediatric.

The distribution channel, which encompasses both online and offline channels, provides the basis for market segmentation.

Regional Perspectives

In 2022, the biggest market share was held by the North American citicoline market. This is because the North American region's senior population is growing, facial correction and improvement surgeries are becoming more common, and per capita disposable income is considerable.

Due to a robust pharmaceutical and healthcare infrastructure, as well as an aging population throughout the region, the European citicoline market holds the second-largest market share. Furthermore, the Spanish citicoline market is anticipated to develop at the fastest rate in the European region, while the German citicoline market was said to have the greatest market share.

From 2024 to 2032, the Asia-Pacific citicoline market is anticipated to expand at a substantial rate. This is a result of the Asia-Pacific region's growing knowledge of cognitive health and the possible advantages of citicoline supplementation. Furthermore, the Asia-Pacific citicoline market is anticipated to grow at the fastest rate in India, while the China market is predicted to hold the greatest market share.

Africa, Latin America, and the Middle East make up the rest of the world. A increasing senior population and more awareness of cognitive health are expected to fuel growth in the aforementioned regions' citicoline markets.

Major Players

Companies like Invision Medi Sciences (India), RPG Life Sciences Ltd (India), CHEMO BIOLOGICAL (India), Century Pharma (India), HARBIN PHARMACEUTICAL GROUP (China), UNION KOREA PHARM CO LTD (South Korea), Kyowa Hakko Bio Co., Ltd (Japan), Vitabiotics Ltd (UK), Grupo Ferrer Internacional, S.A (Spain), and Life Extension (US) are just a few examples.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

  • 1.1 GLOBAL CITICOLINE MARKET, BY PRODUCT
  • 1.2 GLOBAL CITICOLINE MARKET, BY APPLICATION
  • 1.3 GLOBAL CITICOLINE MARKET, BY AGE GROUP
  • 1.4 GLOBAL CITICOLINE MARKET, BY DISTRIBUTION CHANNEL
  • 1.5 GLOBAL CITICOLINE MARKET, BY REGION

2 MARKET INTRODUCTION

  • 2.1 DEFINITION
  • 2.2 SCOPE OF THE STUDY
  • 2.3 MARKET STRUCTURE
  • 2.4 KEY BUYING CRITERIA

3 RESEARCH METHODOLOGY

  • 3.1 RESEARCH PROCESS
  • 3.2 PRIMARY RESEARCH
  • 3.3 SECONDARY RESEARCH
  • 3.4 MARKET SIZE ESTIMATION
  • 3.5 TOP DOWN & BOTTOM-UP APPROACH
  • 3.6 FORECAST MODEL
  • 3.7 LIST OF ASSUMPTIONS

4 MARKET DYNAMICS

  • 4.1 INTRODUCTION
  • 4.2 DRIVERS
    • 4.2.1 RISING AWARENESS OF COGNITIVE HEALTH
    • 4.2.2 GROWING DEMAND FROM FITNESS AND SPORTS INDUSTRIES
    • 4.2.3 DRIVERS IMPACT ANALYSIS
  • 4.3 RESTRAINTS
    • 4.3.1 COMPETITION FROM ALTERNATIVES PRODUCTS
    • 4.3.2 REGULATORY CHALLENGES
    • 4.3.3 RESTRAINTS IMPACT ANALYSIS
  • 4.4 OPPORTUNITY
    • 4.4.1 INCREASING AGING POPULATION
  • 4.5 IMPACT OF COVID-19 ON GLOBAL ECONOMY
  • 4.6 IMPACT OF COVID-19 ON THE GLOBAL CITICOLINE MARKET
  • 4.7 SUPPLY CHAIN IMPACT
    • 4.7.1 IMPACT ON MANUFACTURER/DEVELOPER
    • 4.7.2 IMPACT ON COMPONENT/SERVICES SUPPLIER
    • 4.7.3 IMPACT ON DISTRIBUTION/LOGISTICS
  • 4.8 REGULATORY LANDSCAPE

5 MARKET FACTOR ANALYSIS

  • 5.1 SUPPLY/VALUE CHAIN ANALYSIS
    • 5.1.1 RAW MATERIALS SUPPLIERS
    • 5.1.2 MANUFACTURING & PACKAGING
    • 5.1.3 DISTRIBUTION & SALES CHANNEL
    • 5.1.4 RETAILERS AND END-USERS
  • 5.2 PORTER'S FIVE FORCES MODEL
    • 5.2.1 THREAT OF NEW ENTRANTS
    • 5.2.2 BARGAINING POWER OF SUPPLIERS
    • 5.2.3 BARGAINING POWER OF BUYERS
    • 5.2.4 THREAT OF SUBSTITUTES
    • 5.2.5 INTENSITY OF RIVALRY

6 GLOBAL CITICOLINE MARKET, BY PRODUCT

  • 6.1 OVERVIEW
  • 6.2 GLOBAL CITICOLINE MARKET SIZE, MARKET ESTIMATES & FORECAST BY PRODUCT, 2019-2032
    • 6.2.1 GLOBAL CITICOLINE MARKET SIZE: MARKET ESTIMATES & FORECAST BY PRODUCT, 2019-2032

7 GLOBAL CITICOLINE MARKET, BY APPLICATION

  • 7.1 OVERVIEW
  • 7.2 GLOBAL CITICOLINE MARKET SIZE, MARKET ESTIMATES & FORECAST BY APPLICATION, 2019-2032
    • 7.2.1 GLOBAL CITICOLINE MARKET SIZE: MARKET ESTIMATES & FORECAST BY APPLICATION, 2019-2032

8 GLOBAL CITICOLINE MARKET, BY AGE GROUP

  • 8.1 OVERVIEW
  • 8.2 GLOBAL CITICOLINE MARKET SIZE, MARKET ESTIMATES & FORECAST BY AGE GROUP, 2019-2032
    • 8.2.1 GLOBAL CITICOLINE MARKET SIZE: MARKET ESTIMATES & FORECAST BY AGE GROUP, 2019-2032

9 GLOBAL CITICOLINE MARKET, BY DISTRIBUTION CHANNEL

  • 9.1 OVERVIEW
  • 9.2 GLOBAL CITICOLINE MARKET SIZE, MARKET ESTIMATES & FORECAST BY DISTRIBUTION CHANNEL, 2019-2032
    • 9.2.1 GLOBAL CITICOLINE MARKET SIZE: MARKET ESTIMATES & FORECAST BY DISTRIBUTION CHANNEL, 2019-2032

10 GLOBAL CITICOLINE MARKET, BY REGION

  • 10.1 OVERVIEW
  • 10.2 NORTH AMERICA
    • 10.2.1 U.S.
    • 10.2.2 CANADA
  • 10.3 EUROPE
    • 10.3.1 GERMANY
    • 10.3.2 FRANCE
    • 10.3.3 UK
    • 10.3.4 ITALY
    • 10.3.5 SPAIN
    • 10.3.6 REST OF EUROPE
  • 10.4 ASIA PACIFIC
    • 10.4.1 CHINA
    • 10.4.2 INDIA
    • 10.4.3 JAPAN
    • 10.4.4 AUSTRALIA
    • 10.4.5 SOUTH KOREA
    • 10.4.6 REST OF ASIA PACIFIC
  • 10.5 REST OF THE WORLD
    • 10.5.1 MIDDLE EAST
    • 10.5.2 AFRICA
    • 10.5.3 LATIN AMERICA
    • 10.5.4 CENTRAL AMERICA

11 COMPETITIVE LANDSCAPE

  • 11.1 COMPETITIVE OVERVIEW
  • 11.2 COMPETITIVE BENCHMARKING
  • 11.3 MAJOR PLAYERS IN THE GLOBAL CITICOLINE MARKET

12 COMPANY PROFILES

  • 12.1 KYOWA HAKKO BIO CO., LTD.
    • 12.1.1 COMPANY OVERVIEW
    • 12.1.2 FINANCIAL OVERVIEW
    • 12.1.3 PRODUCTS OFFERED
    • 12.1.4 KEY DEVELOPMENTS
    • 12.1.5 SWOT ANALYSIS
    • 12.1.6 KEY STRATEGIES
  • 12.2 VITABIOTICS LTD
    • 12.2.1 COMPANY OVERVIEW
    • 12.2.2 FINANCIAL OVERVIEW
    • 12.2.3 PRODUCTS OFFERED
    • 12.2.4 KEY DEVELOPMENTS
    • 12.2.5 SWOT ANALYSIS
    • 12.2.6 KEY STRATEGIES
  • 12.3 GRUPO FERRER INTERNACIONAL, S.A.
    • 12.3.1 COMPANY OVERVIEW
    • 12.3.2 FINANCIAL OVERVIEW
    • 12.3.3 PRODUCTS OFFERED
    • 12.3.4 KEY DEVELOPMENTS
    • 12.3.5 SWOT ANALYSIS
    • 12.3.6 KEY STRATEGIES
  • 12.4 LIFE EXTENSION
    • 12.4.1 COMPANY OVERVIEW
    • 12.4.2 FINANCIAL OVERVIEW
    • 12.4.3 PRODUCTS/SERVICES OFFERED
    • 12.4.4 KEY DEVELOPMENTS
    • 12.4.5 SWOT ANALYSIS
    • 12.4.6 KEY STRATEGIES
  • 12.5 UNION KOREA PHARM CO LTD
    • 12.5.1 COMPANY OVERVIEW
    • 12.5.2 FINANCIAL OVERVIEW
    • 12.5.3 PRODUCTS/SERVICES OFFERED
    • 12.5.4 KEY DEVELOPMENTS
    • 12.5.5 SWOT ANALYSIS
    • 12.5.6 KEY STRATEGIES
  • 12.6 INVISION MEDI SCIENCES
    • 12.6.1 COMPANY OVERVIEW
    • 12.6.2 FINANCIAL OVERVIEW
    • 12.6.3 PRODUCTS/SERVICES OFFERED
    • 12.6.4 KEY DEVELOPMENTS
    • 12.6.5 SWOT ANALYSIS
    • 12.6.6 KEY STRATEGIES
  • 12.7 RPG LIFE SCIENCES LTD
    • 12.7.1 COMPANY OVERVIEW
    • 12.7.2 FINANCIAL OVERVIEW
    • 12.7.3 PRODUCTS/SERVICES OFFERED
    • 12.7.4 KEY DEVELOPMENTS
    • 12.7.5 SWOT ANALYSIS
    • 12.7.6 KEY STRATEGIES
  • 12.8 CHEMO BIOLOGICAL
    • 12.8.1 COMPANY OVERVIEW
    • 12.8.2 FINANCIAL OVERVIEW
    • 12.8.3 PRODUCTS OFFERED
    • 12.8.4 KEY DEVELOPMENTS
    • 12.8.5 SWOT ANALYSIS
    • 12.8.6 KEY STRATEGIES
  • 12.9 CENTURY PHARMA
    • 12.9.1 COMPANY OVERVIEW
    • 12.9.2 FINANCIAL OVERVIEW
    • 12.9.3 PRODUCTS/SERVICES OFFERED
    • 12.9.4 KEY DEVELOPMENTS
    • 12.9.5 SWOT ANALYSIS
    • 12.9.6 KEY STRATEGIES
  • 12.10 HARBIN PHARMACEUTICAL GROUP
    • 12.10.1 COMPANY OVERVIEW
    • 12.10.2 FINANCIAL OVERVIEW
    • 12.10.3 PRODUCTS OFFERED
    • 12.10.4 KEY DEVELOPMENTS
    • 12.10.5 SWOT ANALYSIS
    • 12.10.6 KEY STRATEGIES

13 APPENDIX

  • 13.1 REFERENCES
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦